Rabiet, 20 mg 28 pcs.

Pharmacotherapeutic group

A gastric gland secretion reducing agent – proton pump inhibitor.

The ATC code: A02BC04

Pharmacological properties

Pharmacodynamics

Mechanism of action

Rabeprazole sodium belongs to the class of antisecretory compounds, benzimidazole derivatives. Rabeprazole sodium inhibits gastric juice secretion by specifically inhibiting H⁺/K⁺ ATPase on the secretory surface of gastric parietal cells.

H⁺/K⁺ ATPase is a protein complex that functions as a proton pump, thus rabeprazole sodium is a proton pump inhibitor in the stomach and blocks the final stage of acid production.

This effect is dose-dependent and results in suppression of both basal and stimulated acid secretion regardless of the stimulus. Rabeprazole sodium has no anticholinergic properties.

Antisecretory effects

After oral administration of rabeprazole sodium at a dose of 20 mg, the antisecretory effect develops within 1 hour. Inhibition of basal and stimulated acid secretion 23 hours after the first dose of rabeprazole sodium is 69% and 82%, respectively, and lasts up to 48 hours.

This duration of pharmacodynamic action is much longer than that predicted by the half-life (T½) (approximately 1 hour). This effect may be explained by prolonged binding of the drug substance to H⁺/ K⁺ ATPase of gastric parietal cells.

The magnitude of the inhibitory effect of rabeprazole sodium on hydrochloric acid secretion reaches a plateau after three days of taking rabeprazole sodium. When discontinued, secretory activity is restored within 1-2 days.

The effect on plasma gastrin levels

In clinical trials, patients took 10 or 20 mg of rabeprazole sodium daily for a treatment duration of up to 43 months. Plasma gastrin concentrations were elevated in the first 2 to 8 weeks, reflecting an inhibitory effect on acid secretion. Gastrin concentrations returned to baseline levels usually within 1-2 weeks after discontinuation of treatment.

The effect on enterochromaffin-like cells

. No consistent changes in the morphological structure of enterochromaffin-like cells, severity of gastritis, frequency of atrophic gastritis, intestinal metaplasia or spread of Helicobacter pylori infection were found in human gastric biopsy samples from the antrum and fundus of 500 patients who received rabeprazole sodium or a comparison drug for 8 weeks.

In a study involving more than 400 patients receiving rabeprazole sodium (10 mg/day or 20 mg/day) for up to 1 year, the incidence of hyperplasia was low and comparable to that of omeprazole (20 mg/kg). No cases of adenomatous changes or carcinoid tumors observed in rats were reported.

Systemic effects of rabeprazole sodium on the central nervous system, cardiovascular or respiratory systems have not been detected at this time.

Rabeprazole sodium has been shown to have no effect on thyroid function, carbohydrate metabolism, blood concentrations of parathyroid hormone, and concentrations of cortisol, estrogen, testosterone, prolactin, glucagon, follicle stimulating hormone (FSH), luteinizing hormone (LH), renin, aldosterone and somatotropic hormone when taken orally for 2 weeks.

Pharmacokinetics

Intake

Rabeprazole is rapidly absorbed from the gut, and its maximum plasma concentrations are reached approximately 3.5 h after a 20 mg dose. Changes of maximum plasma concentrations (C_max) of the area under the curve “concentration-time” (AUC) of rabeprazole are linear in the dose range from 10 to 40 mg.

The absolute bioavailability after oral administration of 20 mg (compared to intravenous administration) is approximately 52%. In addition, bioavailability does not change with repeated administration of rabeprazole. In healthy volunteers, the plasma elimination half-life is about 1 h (varying from 0.7 to 1.5 h) and total clearance is 3.8 ml/min/kg.

In patients with chronic liver damage, the AUC is doubled compared to healthy volunteers, indicating decreased first-pass metabolism, and the plasma elimination half-life is increased by 2-3 times. Neither the time of intake of the drug during the day, nor antacids affect absorption of rabeprazole.

Ingestion of the drug with fatty foods reduces absorption of the drug by 4 hours or more, but neither C_max nor the degree of absorption is altered.

Distribution

In humans, the binding of rabeprazole to plasma proteins is about 97%.

Metabolism.

In healthy people. No unchanged rabeprazole was found in the urine after a single oral dose of 20 mg ¹⁴ C -labeled rabeprazole.

About 90% of rabeprazole is excreted through the kidneys, mainly as two metabolites: mercapturic acid conjugate (M5) and carboxylic acid (M6), and in the form of two unknown metabolites identified in the toxicological analysis. The remainder of rabeprazole sodium taken is excreted through the intestine.

The total excretion is 99.8%. These data indicate a small excretion of metabolites of rabeprazole sodium with bile.

The main metabolite is thioether (M1). The only active metabolite is desmethyl (M3), but it was observed in low concentration only in one study participant after administration of 80 mg of rabeprazole sodium.

Terminal stage renal failure

In patients with stable, terminal renal failure who require maintenance hemodialysis (creatinine clearance <5 ml/min/1.73 m²), the excretion of rabeprazole sodium is similar to that of healthy volunteers. The AUC and C_max in these patients were approximately 35% lower than in healthy volunteers.

The average half-life of rabeprazole is 0.82 h in healthy volunteers; 0.95 h in patients during hemodialysis and 3.6 h after hemodialysis.

The clearance of the drug in patients with renal disease requiring hemodialysis was approximately twice as high as in healthy volunteers.

Chronic compensated cirrhosis

Patients with chronic compensated cirrhosis tolerate rabeprazole sodium at a dose of 20 mg once daily, although the AUC is doubled and C_max increased by 50% compared with healthy volunteers of the respective sex.

Elderly patients

The elimination of rabeprazole is somewhat delayed in elderly patients. After 7 days of rabeprazole 20 mg administration, the AUC was approximately twice as high and the C_max increased by 60% compared to young healthy volunteers. However, there was no evidence of cumulation of rabeprazole.

CYP2C19 polymorphism.

In patients with delayed CYP2C19 metabolism, after 7 days of taking rabeprazole at a dose of 20 mg daily, the AUC increased 1.9-fold and the elimination half-life increased 1.6-fold compared to the same parameters in “fast metabolizers,” while C_max is increased by 40%.

.

Indications

Symptoms of dyspepsia associated with increased acidity of gastric juice, including symptoms of gastroesophageal reflux disease.Symptoms of dyspepsia associated with increased gastric acidity, including symptoms of gastroesophageal reflux disease (heartburn, sour belching).

Active ingredient

Composition

1 capsule contains:

Rabeprazole, pellet substance 8.5% 118 mg

Active ingredient: rabeprazole sodium 10 mg;

Excipients: sugar spheres (sucrose 99.83%, povidone 0.17%) 71.46 mg, sodium carbonate 1.66 mg, talc 1.77 mg, titanium dioxide 0.83 mg, hypromellose 14.75 mg;

Pellet shell excipients: hypromellose phthalate 15.94 mg, cetyl alcohol 1.59 mg:

Solid gelatin capsule #3: capsule body – titanium dioxide 2%, gelatin to 100%; capsule cap – titanium dioxide 2%; proprietary blue dye 0.0176%, diamond black dye 0.051%, gelatin to 100%.

How to take, the dosage

The drug is taken orally, preferably in the morning, before meals.

It has been found that neither the time of day nor food intake affects the activity of rabeprazole sodium, but the recommended time of taking rabeprazole helps to improve patient compliance.

The capsules should be swallowed whole without chewing or crushing.

The recommended dose is 10 mg once daily.

If there is no effect after the first 3 days, a specialist should be seen.

The maximum course of treatment without a physician’s consultation is 14 days.

Interaction

The cytochrome 450 system

Sodium rabeprazole, like other proton pump inhibitors, is metabolized with participation of the cytochrome P450 system (CYP450) in the liver. In in vitro studies on human liver microsomes it was shown that rabeprazole sodium is metabolized by CYP2C19 and CYP3A4 isoenzymes.

Studies in healthy volunteers have shown that rabeprazole sodium has no pharmacokinetic or clinically significant interactions with drugs that are metabolized by the cytochrome P450 system – warfarin, phenytoin, theophylline and diazepam (regardless of how diazepam is metabolized in patients, either heavily or weakly).

There was a study of combination therapy with antibiotics. This four-way study involved 16 healthy volunteers who received 20 mg of rabeprazole, 1,000 mg of amoxicillin, 500 mg of clarithromycin, or a combination of these three drugs (RAC – rabeprazole, amoxicillin, clarithromycin).

The AUC and Cmax values for clarithromycin and amoxicillin were similar when comparing combination therapy to monotherapy. The AUC and Cmax for rabeprazole increased by 11% and 34%, respectively, and the AUC and Cmax for 14-hydroxyclarithromycin (the active metabolite of clarithromycin) increased by 42% and 46% for combination therapy compared with monotherapy, respectively.

This increase in exposure to rabeprazole and clarithromycin was not found to be clinically significant.

Interactions due to inhibition of gastric juice secretion

Rabeprazole sodium has sustained and prolonged suppression of gastric juice secretion. Thus, there may be an interaction with substances for which absorption is pH-dependent. When concomitant administration with rabeprazole sodium absorption of ketoconazole is reduced by 30%, and absorption of digoxin is increased by 22%.

Hence, for some patients, monitoring should be conducted to decide whether a dose adjustment is necessary when concomitant use of rabeprazole sodium with ketoconazole, digoxin or other drugs for which absorption depends on pH.

Atazanavir

Concomitant administration of atazanavir 300 mg/ritonavir 100 mg with omeprazole (40 mg once daily) or atazanavir 400 mg with lansoprazole (60 mg once daily) in healthy volunteers showed a significant decrease in atazanavir exposure. Atazanavir absorption is pH dependent.

While concomitant administration with rabeprazole has not been studied, similar results are also expected for proton pump inhibitors. Thus, concomitant use of atazanavir with proton pump inhibitors, including rabeprazole, is not recommended.

Antacids

In clinical trials antacids were used together with rabeprazole sodium. No clinically significant interaction of rabeprazole sodium with aluminum hydroxide gel or magnesium hydroxide was observed.

In a clinical study, no clinically significant interaction was observed during administration of rabeprazole sodium with fat-dense food. Administration of rabeprazole sodium concomitantly with fat-rich food may delay absorption of rabeprazole up to 4 hours or more, but Cmax and AUC are not changed.

Cyclosporine

In vitro experiments using human liver microsomes showed that rabeprazole inhibited the metabolism of cyclosporine with an IC50 of 62 μmol, i.e. at a concentration 50 times the Cmax for healthy volunteers after 20 days of rabeprazole dosing of 20 mg. The degree of inhibition is similar to that of omeprazole for equivalent concentrations.

Methotrexate

. According to reports of adverse events, published pharmacokinetic studies, and retrospective analysis, concomitant administration of proton pump inhibitors and methotrexate (especially in high doses) may lead to increased concentrations of methotrexate and/or its metabolite hydroxy-methotrexate and prolong its elimination time.

However, there have been no specific studies of drug interactions of methotrexate with proton pump inhibitors.

Special Instructions

Patient response to therapy with rabeprazole sodium does not exclude the presence of gastric malignancy.

In a special study in patients with mild to moderate hepatic impairment no significant difference in the incidence of side effects of rabeprazole was found compared to that in gender- and age-matched healthy subjects, but despite this, caution is recommended when first using Rabiet® in patients with severe hepatic impairment.

Patients with impaired renal or hepatic function do not require dose adjustment of Rabiet®. The AUC of rabeprazole sodium in patients with severe hepatic impairment is approximately 2 times higher than in healthy patients.

Hypomagnesemia

When treated with proton pump inhibitors for at least 3 months, cases of symptomatic or asymptomatic hypomagnesemia have rarely been reported. In most cases, these reports came one year after therapy. Serious adverse events were tetany, arrhythmias, and seizures.

The majority of patients required treatment for hypomagnesemia, which included magnesium replacement and proton pump inhibitor withdrawal. In patients who will receive long-term treatment or who take proton pump inhibitors with drugs such as digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), magnesium concentrations should be monitored before treatment with proton pump inhibitors and during treatment.

Do not take other acid-reducing medications, such as H2-histamine receptor blockers or proton pump inhibitors, concomitantly with Rabiet®.

Bone fractures

Observational studies suggest that therapy with proton pump inhibitors may increase the risk of osteoporosis-related fractures of the hip, wrist, or spine. The risk of fracture was increased in patients who received high-dose proton pump inhibitors for a long period of time (one year or more). High should be understood to mean doses higher than those recommended in the instructions.

Concomitant use with methotrexate

According to the literature, concomitant use of proton pump inhibitors with methotrexate (especially in high doses) may lead to increased concentration of methotrexate and/or its metabolite hydroxytetrexate and prolong its elimination time, which may lead to methotrexate toxicity. Temporary discontinuation of therapy with proton pump inhibitors may be considered if high doses of methotrexate are necessary.

Clostridium difficile

Therapy with proton pump inhibitors may lead to an increased risk of gastrointestinal infections, such as those caused by Clostridium difficile.

Patients taking rabeprazole for short-term symptomatic treatment of manifestations of GERD and NERD (e.g., heartburn) without a prescription should consult a physician in the following cases:

– use of medications to relieve symptoms of heartburn and digestive disturbances for 4 weeks or more;

– occurrence of new symptoms or changes in previously observed symptoms in patients over 55 years of age;

– cases of unintentional weight loss, anemia, gastrointestinal bleeding, dysphagia, pain when swallowing, persistent vomiting or vomiting with blood and gastric contents, history of gastric ulcers or gastric surgery, jaundice, etc.д. (including impaired liver and kidney function).

Patients with recurrent symptoms of digestive disorders or heartburn should be regularly monitored by a physician. Patients over 55 years of age who take daily over-the-counter medications to relieve symptoms of heartburn and digestive disorders should inform their physician.

Do not take other acid-reducing drugs, such as H2-histamine receptor blockers or proton pump inhibitors, at the same time as rabeprazole.

Patients should consult their pharmacist or physician before starting over-the-counter therapy with Rabiet® when using other drugs.

Patients should tell their physician before starting Rabiet® without a prescription if they are scheduled for an endoscopic exam.

Patients should avoid taking Rabiet® prior to performing a urea breath test.

Patients with severe hepatic impairment should see their physician before starting over-the-counter therapy with Rabiet® for short-term symptomatic treatment of GERD and NERD symptoms (e.g., heartburn).

Influence on driving and operating machinery

Based on the specific pharmacodynamics of rabeprazole and its adverse effect profile, it is unlikely that rabeprazole affects the ability to drive and operate machinery. However, in case of drowsiness, these activities should be avoided.

Contraindications

Deficiency of sucrose/isomaltase, fructose intolerance, glucose-galactose malabsorption syndrome;

pregnancy;

breastfeeding period;

age less than 18 years;

hypersensitivity to rabeprazole, substituted benzimidazoles or to the excipients of the drug.

The drug should be prescribed with caution in severe renal failure.

Side effects

Based on the experience of clinical studies, it can be concluded that rabeprazole is usually well tolerated by patients. Side effects are generally mild to moderate and transient.

The following side effects have been reported with rabeprazole in clinical trials.

Nervous system disorders: headache, dizziness.

Digestive system disorders: abdominal pain, diarrhea, flatulence, constipation, dry mouth.

Others: rash, peripheral edema.

The following side effects have been reported during post-registration use of the drug.

Digestive system disorders: increased activity of liver enzymes; rarely – hepatitis, jaundice. In patients with liver cirrhosis the development of hepatic encephalopathy has been rarely reported.

Hematopoietic system: rare – thrombocytopenia, neutropenia, leukopenia.

Muscular system: rare – myalgia, arthralgia.

Allergic reactions: rare – bullous rashes, urticaria, acute systemic allergic reactions; very rare – erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome.

Others: rare – hypomagnesemia; very rare – development of interstitial nephritis, gynecomastia.

There have been no changes in other laboratory parameters during administration of Rabeprazole sodium.

According to post-marketing surveillance data, proton pump inhibitors may increase the risk of fractures.

Overdose

The data on intentional or accidental overdose are minimal.

There have been no cases of severe overdose of rabeprazole.

Treatment: conduct symptomatic and supportive therapy.

The specific antidote for rabeprazole is unknown.

Rabeprazole binds well to plasma proteins and is therefore poorly excreted by dialysis.

Pregnancy use

There are no data on the safety of rabeprazole in pregnancy. Reproduction studies in rats and rabbits showed no evidence of fertility abnormalities or fetal defects caused by rabeprazole; however, in rats the drug penetrates the placental barrier in small amounts.

The drug Rabiet® should not be used in pregnancy unless the expected benefits to the mother outweigh the possible risk to the fetus.

It is unknown whether rabeprazole is excreted with the breast milk. Corresponding studies in women during breastfeeding have not been conducted. However, rabeprazole is found in the milk of lactating rats, therefore Rabiet® should not be administered to women during breastfeeding.

Similarities